课题基金 / 基金详情

CYTOSOL ACTIVATOR OF RAT RETICULOCYTE ADENYLATE CYCLASE

CYTOSOL ACTIVATOR OF RAT RETICULOCYTE ADENYLATE CYCLASE
大鼠网状细胞腺苷酸环化酶的胞质激活剂
批准号:
3229846
负责人:
Elizabeth J Shane
金额:
$14.05万
依托单位国家:
美国
项目类别:
财政年份:
1981
资助国家:
美国
项目状态:
已结题
起止时间:
1981-09-01 至 1989-08-31

项目摘要

项目成果

Elizabeth J Shane的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this research project is to establish the identity, mechanism of action, and importance of the cellular regulator of adenylate cyclase obtained from the cytosol of rat reticulocytes. The reticulocyte cytosol activator protein (RCAP), that augments catecholamine-sensitive adenylate cyclase in rat reticulocyte membranes, has been only partially purified and characterized. The goals of the research plan are to purify and to completely characterize RCAP; to elucidate the mechanisms by which it so profoundly influences catecholamine responsiveness; and to establish to what extent, and by what means, RCAP regulates adenylate cyclase activity in other tissues and species. RCAP will be purified to homogeneity using established biochemical techniques including preparative isoelectric focusing and other specific approaches outlined in Methods. The mechanism of action of RCAP will be investigated by studies directed at RCAP's effects upon each of the three components of the hormonal unit, the beta-adrenergic receptor, the guanine nucleotide coupling protein, and the catalytic unit of adenylate cyclase, as well as the interactions among them. Specific methods will include radioligand binding studies, determination of adenylate cyclase activity, and assessment of the guanine nucleotide binding protein by means of the ADP-ribosylation assay. The effects of RCAP upon other hormones that stimulate or inhibit adenylate cyclase and in several other mammalian and tissues will also be investigated in order to determine the importance of RCAP as a general regulator of hormone action.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase 2b Study of Denosumab to Prevent Bone Loss in Idiopathic Osteoporosis in Premenopausal Women Treated with Teriparatide
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
海外基金